1. MULTI-CHANNEL BRAIN OR CORTICAL ACTIVITY MONITORING AND METHOD
US 11,553,869 B1
Inventors:
Stéphane Bibian, Tatjana Zikov
Assignee:
NeuroWave Systems Inc.
Date of Patent:
Jan. 17, 2023
This patent describes a system and method for monitoring and displaying the neuropathological characteristics and activity of both sides of a subject’s brain simultaneously. It enables the identification and treatment of neurophysiological conditions or brain dysfunction, making it useful for seizure detection, sedation monitoring, anesthesia monitoring, and more.
2. SYSTEM FOR VARIABLY CONFIGURABLE, ADAPTABLE ELECTRODE ARRAYS AND SOFTWARE
US 11,633,595 B2
Inventor:
Michael P. Weisend
Assignee:
STIMSCIENCE INC.
Date of Patent:
Apr. 25, 2023
This patent focuses on electrical non-invasive brain stimulation (NIBS) using electrode arrays placed on the scalp. The system is adaptable and configurable to enhance brain performance, treat neurological diseases, and target specific brain areas or networks. It employs modern electrodes with different spatial arrangements, polarities, and current strengths.
3. METHOD FOR INTERPRETING WORDS, PHRASES, AND COMMANDS FROM BRAIN ACTIVITY
US 11,662,819 B2
Inventor:
Robert A. Connor
Assignee:
Medibotics
Date of Patent:
May 30, 2023
This non-invasive Brain to Computer Interface (BCI) method interprets words, phrases, or commands from brain activity patterns. It identifies the specific electromagnetic brain activity patterns that occur when a person communicates using different action modalities, enabling communication for individuals with neuromuscular limitations or paralysis.
4. METHOD FOR DETECTING CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE
US 11,666,285 B2
Inventor:
Nadia Mammone, Francesco Carlo Morabito, Placido Bramanti, Alessia Bramanti, Maurizio Campolo, Cosimo Ieracitano, Lilla Bonanno
Assignee:
IRCCS CENTRO NEUROLESI “BONINO-PULEJO”
Date of Patent:
Jun. 6, 2023
This patent describes a data processing method for objectively detecting the conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) by quantifying the effects on a patient’s electroencephalogram (EEG). It provides an objective criterion for monitoring the brain health status of MCI subjects.
Our Experts
Gina Arias
Regulatory Affairs Manager
